.png)
Professor Sahika Inal, associate professor of bioengineering
Photo Credit: Courtesy of King Abdullah University of Science and Technology
Scientific Frontline: Extended "At a Glance" Summary: Blood-Based Electronic Sensor for Parkinson's Disease
The Core Concept: A highly sensitive electronic sensor, utilizing an organic electrochemical transistor, that detects trace molecular signatures of Parkinson's disease in blood samples.
Key Distinction/Mechanism: Unlike conventional clinical assessments that rely on the emergence of physical symptoms, this technology isolates tiny vesicles released by nerve cells into the blood. A transistor amplifies minute biological signals into larger electronic signals, allowing the simultaneous measurement of three forms of the alpha-synuclein protein within 40 minutes while bypassing heavy background noise from red blood cells.
Origin/History: Developed collaboratively by bioengineers at the King Abdullah University of Science and Technology (KAUST) and researchers at the University of Oxford, with initial findings published in Science Advances in October 2026.
Major Frameworks/Components:
- Organic electrochemical transistor (OECT) technology for biological signal amplification.
- Isolation of nerve-derived packages from the peripheral blood flow.
- Multiplexed detection of distinct structural forms of alpha-synuclein.
Branch of Science: Bioengineering, Neurology, and Biomedical Diagnostics.
Future Application: The development of accessible, routine clinical blood tests to identify age-related neurodegenerative diseases, including isolated REM sleep behavior disorder, well before the onset of overt motor symptoms.
Why It Matters: Parkinson's disease damages dopamine-producing neurons long before a diagnosis is typically made. By achieving a 90.9 percent diagnostic accuracy in an initial cohort, this platform offers a noninvasive method for earlier detection, which is crucial for preventive healthcare and timely therapeutic intervention.
.png) |
| The organic electrochemical transistor (OECT) sensor, showing its gate electrodes and OECT channels. Image Credit: Courtesy of King Abdullah University of Science and Technology |
Researchers at King Abdullah University of Science and Technology (KAUST), in collaboration with the University of Oxford, have developed a blood-based electronic sensor capable of detecting molecular signatures associated with Parkinson’s disease.
Published in Science Advances, the technology uses a highly sensitive electronic sensor developed at KAUST to simultaneously detect three different forms of alpha-synuclein, a protein closely associated with Parkinson’s disease. The sensor can detect these proteins at extremely low concentrations that are difficult to measure using conventional analytical techniques.
The approach first isolates tiny packages released by nerve cells into the bloodstream before their protein contents are analyzed using the electronic sensor. At the heart of the technology is a transistor that amplifies very small biological signals into much larger electronic signals, allowing all three forms of alpha-synuclein to be measured within 40 minutes.
Parkinson’s damages dopamine-producing neurons, leading to problems with movement, balance, and other bodily functions. It is currently diagnosed largely through clinical assessment, often after characteristic movement symptoms have emerged.
Detecting disease-related proteins originating from the brain could offer an earlier window into the disease, but measuring them in blood is extremely difficult because more than 95 percent of circulating alpha-synuclein originates from red blood cells, creating heavy background noise.
Saudi Arabia’s healthcare system is placing increasing emphasis on prevention and earlier detection as people live longer. Life expectancy in the Kingdom has risen to 79.7 years, approaching the Saudi Vision 2030 target of 80, while the proportion of older people is expected to grow significantly in the coming decades.
Against this backdrop, technologies that could eventually help identify age-related diseases such as Parkinson’s earlier could become increasingly relevant to long-term healthcare.
In a blinded evaluation involving 59 participants from the Oxford Discovery cohort, the platform achieved 90.9 percent accuracy in distinguishing disease-associated profiles from healthy controls.
The study included people diagnosed with Parkinson’s disease, healthy controls, and individuals with isolated REM sleep behavior disorder, a condition in which people physically act out their dreams and which is associated with an increased risk of developing Parkinson’s or related neurological disorders.
Researchers found distinct patterns in the different forms of alpha-synuclein across the groups, suggesting that measuring them together could provide more useful diagnostic information than relying on a single marker.
“Changes associated with Parkinson’s can begin long before a clinical diagnosis, but detecting those changes through something as accessible as blood remains extremely challenging,” said Professor Sahika Inal, associate professor of bioengineering at KAUST.
“Our approach allows us to detect several forms of alpha-synuclein together at extremely low concentrations. These early results are encouraging, and the next step is to validate the technology in much larger groups of patients.”
The researchers caution that the technology is not yet a standalone clinical blood test. The current study represents a retrospective evaluation in an initial cohort, and larger, prospective, multicenter clinical studies will be needed to establish its long-term predictive value before the platform could be used routinely in healthcare.
Published in journal: Science Advances
Authors: Tianrui Chang, Cheng Jiang, Shijun Yan, Shofarul Wustoni, Luca Salvigni, Rania Almaghrabi, Michele T. Hu, George K. Tofaris, Keying Guo, and Sahika Inal
Source/Credit: King Abdullah University of Science and Technology
Edited by: Scientific Frontline
Reference Number: beng100526_01
.jpg)
